Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | CASP1 | P29466 | 1/20 | 0.60 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.60 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.60 |
| ▸ | CNR2 | P34972 | 6/20 | 0.47 |
| ▸ | CNR1 | P21554 | 5/20 | 0.47 |
| ▸ | APP | P05067 | 5/20 | 0.44 |
| ▸ | RARB | P10826 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9776310 | 1.00 | CYP3A4 (0.60) | CYP3A4SMN1; SMN2MEN1KMT2AUSP2 | |
| SCHEMBL4074135 | 0.91 | CYP3A4 (0.62) | CYP3A4SMN1; SMN2MEN1KMT2AUSP2 | |
| SCHEMBL2108030 | 0.88 | CYP3A4 (0.54) | CYP3A4SMN1; SMN2CNR2CNR1NR5A1 | |
| SCHEMBL1592413 | 0.87 | CYP3A4 (0.53) | CYP3A4SMN1; SMN2CNR2CNR1TSHR | |
| SCHEMBL9299799 | 0.86 | CNR2 (0.44) | CYP3A4SMN1; SMN2MEN1KMT2AUSP2 | |
| SCHEMBL10492948 | 0.85 | NR5A1 (0.53) | CNR2CNR1NR5A1 | |
| SCHEMBL14968565 | 0.84 | MEN1 (0.66) | CYP3A4SMN1; SMN2MEN1KMT2AUSP2 | |
| SCHEMBL1890228 | 0.84 | CNR2 (0.47) | CYP3A4SMN1; SMN2ALDH1A1CNR2CNR1 | |
| SCHEMBL10513794 | 0.84 | NR5A1 (0.56) | CNR2CNR1TSHRNR5A1 | |
| SCHEMBL11085658 | 0.83 | S1PR1 (0.54) | CYP3A4SMN1; SMN2MEN1KMT2AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120142641-A | CUT & Tag library building method for frozen tissue | 中国科学院昆明动物研究所 | 2025-06-13 | — | — | CN | claimed |
| CN-120060236-A | Kit for separating nuclei of liver tissues and separation method of nuclei | 南京江北新区生物医药公共服务平台有限公司 | 2025-05-30 | — | — | CN | claimed |
| EP-4448787-B1 | GENOTYPING OF TARGETED LOCI WITH SINGLE-CELL CHROMATIN ACCESSIBILITY | UNIV CORNELL (US) | 2026-05-20 | — | — | EP | disclosed |
| WO-2026089602-A1 | IMPROVED METHOD FOR GENERATING INNER EAR ORGANOIDS | ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) (NL) | 2026-04-30 | — | — | WO | disclosed |
| EP-4732018-A1 | METHODS FOR DIAGNOSING FIBROTIC NASH | Academisch Ziekenhuis Leiden (h.o.d.n. LUMC) (NL) | 2026-04-29 | — | — | EP | disclosed |
| US-12589387-B2 | Integrated fluidic devices and related methods | HELIXBIND, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| EP-4695346-A1 | POLOXAMER-STABILIZED REAGENTS | Promega Corporation (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4695399-A2 | VOLTAGE GATED SODIUM CHANNEL-SPECIFIC PEPTIDE APTAMERS AND USES THEREOF | The Medical College of Wisconsin, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260009068-A1 | METHODS FOR BARCODING MACROMOLECULES IN INDIVIDUAL CELLS | Encodia, Inc. (US) | 2026-01-08 | — | — | US | disclosed |
| US-12516387-B2 | Methods and devices for identifying microbial infections | HELIXBIND, INC. (US) | 2026-01-06 | — | — | US | disclosed |
| US-20250382591-A1 | BST POLYMERASES WITH REVERSE TRANSCRIPTASE ACTIVITY | Varigen Biosciences dba Varizymes (US) | 2025-12-18 | — | — | US | disclosed |
| US-20220153730-A9 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-05-19 | — | — | US | disclosed |
| US-11311622-B2 | Development of masked therapeutic antibodies to limit off-target effects | CITY OF HOPE (US) | 2022-04-26 | — | — | US | disclosed |
| WO-2022081920-A1 | SYSTEMS FOR AND METHODS OF TREATMENT SELECTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-21 | — | — | WO | disclosed |
| EP-3983000-A1 | SYSTEMS AND METHODS FOR IN VIVO DUAL RECOMBINASE-MEDIATED CASSETTE EXCHANGE (DRMCE) AND DISEASE MODELS THEREOF | Cedars-Sinai Medical Center (US) | 2022-04-20 | — | — | EP | disclosed |
| CN-109414695-B | Integrated fluidic devices and related methods | 海利克斯拜恩德股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
| WO-2022046576-A1 | PANCREATIC DUCTAL ADENOCARCINOMA SIGNATURES AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
| EP-3956479-A1 | METHODS AND DEVICES FOR ULTRASENSITIVE DIRECT DETECTION OF MICROORGANISMS | Helixbind, Inc. (US) | 2022-02-23 | — | — | EP | disclosed |
| US-11254966-B2 | Cysteine labelling | UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) | 2022-02-22 | — | — | US | disclosed |
| US-20220040222-A1 | TREATMENT FOR METHAMPHETAMINE CARDIOVASCULAR DISEASE | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260009068-A1 | METHODS FOR BARCODING MACROMOLECULES IN INDIVIDUAL CELLS | HNRNPAB, ACTB, SSBP1 | CYP3A4 4873/4885SMN1; SMN2 3047/4885MEN1 3290/4885 |
| US-12589387-B2 | Integrated fluidic devices and related methods | CD47, EXOSC4, DIS3 | CYP3A4 4853/4885SMN1; SMN2 818/4885MEN1 1024/4885 |
| US-20220040222-A1 | TREATMENT FOR METHAMPHETAMINE CARDIOVASCULAR DISEASE | STS, TST, MPST | CYP3A4 370/4885SMN1; SMN2 1837/4885MEN1 2672/4885 |
| US-20220153730-A9 | INHIBITORS OF C-JUN-N-TERMINAL KINASE (JNK) | CNKSR1, MAPK1, MAP3K1 | CYP3A4 3824/4885SMN1; SMN2 1963/4885MEN1 2830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.